EnGeneIC Molecular Delivery Pty Ltd
Records under this name other than the patents EnGeneIC Molecular Delivery Pty Ltd holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 20 patents it holds.
Back to EnGeneIC Molecular Delivery Pty Ltd
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,772,013 | Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells Term ended Term ended May 11, 2026 · From the USPTO record | Term ended | Term ended May 11, 2026 | From the USPTO record |
| US 8,735,566 | Bacterially derived intact minicells that encompass plasmid free functional nucleic acid for in vivo delivery to mammalian cells Term ended Term ended Jan 14, 2026 · From the USPTO record | Term ended | Term ended Jan 14, 2026 | From the USPTO record |
| US 8,669,101 | Bacterially derived intact minicells that encompass plasmid free functional nucleic acid for in vivo delivery to mammalian cells Term ended Term ended Oct 12, 2025 · From the USPTO record | Term ended | Term ended Oct 12, 2025 | From the USPTO record |
| US 8,956,864 | Bacterially Derived Intact Minicells That Encompass Plasmid Free Functional Nucleic Acid for in Vivo Delivery to Mammalian Cells Term ended Ended no later than Aug 25, 2025 · Low confidence | Term ended | Ended no later than Aug 25, 2025 | Low confidence |
| US 9,066,982 | Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells Term ended Ended no later than Aug 25, 2025 · From the USPTO record | Term ended | Ended no later than Aug 25, 2025 | From the USPTO record |
| US 9,242,007 | Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells Term ended Term ended Aug 25, 2025 · From the USPTO record | Term ended | Term ended Aug 25, 2025 | From the USPTO record |
| US 9,730,897 | Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells Term ended Term ended Aug 25, 2025 · From the USPTO record | Term ended | Term ended Aug 25, 2025 | From the USPTO record |
| US 10,098,847 | Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells Term ended Ended no later than Aug 25, 2025 · From the USPTO record | Term ended | Ended no later than Aug 25, 2025 | From the USPTO record |
| US 10,383,827 | Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells Term ended Term ended Aug 25, 2025 · From the USPTO record | Term ended | Term ended Aug 25, 2025 | From the USPTO record |
| US 10,426,736 | Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells Term ended Ended no later than Aug 25, 2025 · From the USPTO record | Term ended | Ended no later than Aug 25, 2025 | From the USPTO record |